• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Policy. OPV cessation--the final step to a "polio-free" world.

作者信息

Aylward R Bruce, Sutter Roland W, Heymann David L

机构信息

Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland.

出版信息

Science. 2005 Oct 28;310(5748):625-6. doi: 10.1126/science.1115547.

DOI:10.1126/science.1115547
PMID:16254173
Abstract

The 20-year, U.S. $4 billion-dollar international effort to eradicate wild polioviruses now includes monovalent oral poliovirus type 1 vaccine (mOPV1), which was first given to 40 million children in India in April 2005. As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis. This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines.

摘要

相似文献

1
Policy. OPV cessation--the final step to a "polio-free" world.
Science. 2005 Oct 28;310(5748):625-6. doi: 10.1126/science.1115547.
2
A vision of a world without polio: the OPV cessation strategy.一个无脊髓灰质炎世界的愿景：口服脊髓灰质炎疫苗停用策略。
Biologicals. 2006 Jun;34(2):75-9. doi: 10.1016/j.biologicals.2006.03.005. Epub 2006 May 8.
3
Risk management in a polio-free world.无脊髓灰质炎世界中的风险管理。
Risk Anal. 2006 Dec;26(6):1441-8. doi: 10.1111/j.1539-6924.2006.00840.x.
4
Progress toward interruption of wild poliovirus transmission--worldwide, January 2007-April 2008.2007年1月至2008年4月全球野生脊髓灰质炎病毒传播阻断进展情况
MMWR Morb Mortal Wkly Rep. 2008 May 9;57(18):489-94.
5
Role of genetic factors in polio eradication: new challenge for policy makers.遗传因素在根除脊髓灰质炎中的作用：政策制定者面临的新挑战。
Vaccine. 2007 Dec 5;25(50):8365-71. doi: 10.1016/j.vaccine.2007.09.068. Epub 2007 Oct 17.
6
Polio eradication: the OPV paradox.消灭脊髓灰质炎：口服脊髓灰质炎疫苗的悖论
Rev Med Virol. 2003 Sep-Oct;13(5):277-91. doi: 10.1002/rmv.401.
7
A case for developing antiviral drugs against polio.研发抗脊髓灰质炎病毒药物的理由。
Antiviral Res. 2008 Sep;79(3):179-87. doi: 10.1016/j.antiviral.2008.04.002. Epub 2008 May 13.
8
[End phase challenges of poliomyelitis eradication programme realization].[实现脊髓灰质炎根除计划的末期挑战]
Przegl Epidemiol. 2005;59(1):59-68.
9
Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.口服脊髓灰质炎病毒疫苗株在人体繁殖过程中的分子进化及其对全球根除脊髓灰质炎病毒的可能影响。
Acta Virol. 2000 Apr;44(2):109-17.
10
Global Polio Eradication Initiative Strategic Plan, 2004.《全球根除脊髓灰质炎行动倡议战略计划，2004年》
MMWR Morb Mortal Wkly Rep. 2004 Feb 13;53(5):107-8.

引用本文的文献

1
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.单价口服脊髓灰质炎疫苗、部分灭活脊髓灰质炎疫苗和双价口服脊髓灰质炎疫苗诱导的 1 型脊髓灰质炎病毒全身体液免疫和肠道黏膜免疫：一项随机对照试验。
Vaccine. 2023 Sep 22;41(41):6083-6092. doi: 10.1016/j.vaccine.2023.08.055. Epub 2023 Aug 29.
2
Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.灭活脊灰病毒疫苗全剂量和半剂量用于常规免疫和暴发应对的免疫原性：一项开放标签、随机对照试验。
Lancet. 2019 Jun 29;393(10191):2624-2634. doi: 10.1016/S0140-6736(19)30503-3. Epub 2019 May 16.
3
The impact of supplementary immunization activities on routine vaccination coverage: An instrumental variable analysis in five low-income countries.补充免疫活动对常规疫苗接种覆盖率的影响：五个低收入国家的工具变量分析。
PLoS One. 2019 Feb 14;14(2):e0212049. doi: 10.1371/journal.pone.0212049. eCollection 2019.
4
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.在消灭脊髓灰质炎的最后阶段管理循环疫苗衍生脊髓灰质炎病毒的风险：口服脊髓灰质炎疫苗的需求
BMC Infect Dis. 2015 Sep 24;15:390. doi: 10.1186/s12879-015-1114-6.
5
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.全球同步停止三种口服脊髓灰质炎病毒疫苗血清型接种的不同时间安排所带来的健康和经济后果。
BMC Infect Dis. 2015 Sep 17;15:374. doi: 10.1186/s12879-015-1113-7.
6
Viral Aetiology of Acute Flaccid Paralysis Surveillance Cases, before and after Vaccine Policy Change from Oral Polio Vaccine to Inactivated Polio Vaccine.疫苗政策从口服脊髓灰质炎疫苗改为灭活脊髓灰质炎疫苗前后急性弛缓性麻痹监测病例的病毒病因学
J Trop Med. 2014;2014:814908. doi: 10.1155/2014/814908. Epub 2014 Mar 19.
7
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.脊髓灰质炎病毒免疫和传播的回顾与评估：知识空白的综合分析与研究需求的确定。
Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28.
8
Modeling population immunity to support efforts to end the transmission of live polioviruses.建立人群免疫模型以支持消灭活脊髓灰质炎病毒传播的努力。
Risk Anal. 2013 Apr;33(4):647-63. doi: 10.1111/j.1539-6924.2012.01891.x. Epub 2012 Sep 17.
9
Free, at last! The progress of new disease eradication campaigns for Guinea worm disease and polio, and the prospect of tackling other diseases.终于自由了！几内亚蠕虫病和脊髓灰质炎新疾病根除运动的进展，以及应对其他疾病的前景。
EMBO Rep. 2009 Mar;10(3):215-21. doi: 10.1038/embor.2009.19.
10
The risks, costs, and benefits of possible future global policies for managing polioviruses.未来全球管理脊髓灰质炎病毒可能采取的政策所带来的风险、成本和益处。
Am J Public Health. 2008 Jul;98(7):1322-30. doi: 10.2105/AJPH.2007.122192. Epub 2008 May 29.